Please login to the form below

Not currently logged in

Galapagos and Janssen end inflammation alliance

Galapagos regains right to GLPG1690

GalapagosJanssen and Galapagos have mutually agreed to terminate their inflammation alliance and option agreements. 

Alongside other candidates, Galapagos will obtain all rights to drug GLPG1690, a selective autotaxin inhibitor preparing for phase II clinical trial in idiopathic pulmonary fibrosis (IPF), a chronic and ultimately fatal disease characterised by a progressive decline in lung function. 

Dr Piet Wigerinck, chief scientific officer at Galapagos, commented: “We are pleased to regain the rights to GLPG1690 to pursue the most suitable clinical application of autotaxin inhibition. 

“The alliance with Janssen has been underway since October 2007 and has generated three clinical molecules, two of which are now proprietary phase II assets of Galapagos: GLPG1205 and GLPG1690. This programme is a valuable component of our development portfolio and regaining the rights is a next step in our transformation into a mature biotech company with a proprietary product pipeline.”

Galapagos identified autotaxin as having a key role to play in inflammation with additional studies suggesting it may also be significant against metabolic disease, arthritic pain, oncology and lung disease. 

Article by
Kirstie Pickering

18th March 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...